Multicenter, randomised, placebo-controlled, double-blinded, parallel arm proof-of concept trial of Lixisenatide in patients with early Parkinson’s disease (LIXIPARK - Extension)
Cure Parkinson's
Centre Hospitalier Universitaire de Toulouse
Extension to WM011. Please see above.
6.1 Pharmaceuticals